| |
AASV news
AASV and NPB offer database
to clarify Japanese MRL issue
In cooperation with the AASV’s Pharmaceutical Issues
Committee, the National Pork Board’s Pork Checkoff has
developed and will maintain a searchable database containing
information supplied by pharmaceutical manufacturers providing
recommendations regarding withdrawal times that comply with the new
Japanese maximum residue limits (MRLs). The database can be
accessed at the Pork Board’s Japanese MRL
webpage.1 The database will be updated as new
information is provided and contains an option that allows the
reader to view the recent updates.
The AASV Pharmaceutical Issues Committee met during the Leman
Swine Conference and developed a policy statement outlining
recommendations regarding the use of antibiotics in the finishing
herd and in breeding animals. This statement was approved by the
AASV Board of Directors during their fall meeting.
The key recommendations put forth by the committee are as
follows:
- The withdrawal recommendations included in the database are
based on information provided by the manufacturers of the specific
products and apply only to those products, not to a drug class in
general or to generic equivalents. It is recommended that you only
use the specific products listed in the database during the
finisher phase or in the breeding herd.
- These recommendations assume product usage in accordance with
the label directions. Extra-label use requires the administration
of an extended withdrawal time and data may not be available to
provide reliable withdrawal recommendations for specific products.
It is the responsibility of the prescribing veterinarian to contact
the manufacturer to obtain withdrawal guidelines for extra-label
use.
- Likewise, if a compound is administered via multiple routes
simultaneously (eg, water and injectable), an extended withdrawal
period may also be required. It is recommended that the
veterinarian contact the manufacturer for specific product
withdrawal recommendations.
- In addition, it is recommended that veterinarians review the
quality assurance practices in effect at the farm or within a
production system to minimize the risk of mistakes in drug
deliveries, storage, and administration.
The complete policy statement is available for review on the
AASV website.2
References
1. Pork.org. Japan maximum residue limits (MRLs). Available at:
http://www.pork.org/Producers/JapanMRL.aspx. Accessed
November 2, 2006.
2. American Association of Swine Veterinarians. AASV
recommendations to meet Japanese MRL requirements of US pork.
Available at: http://www.aasv.org/aasv/position-japanMRL.html.
Accessed November 2, 2006.
AASV board approves porcine circovirus position statement
At its fall meeting, the AASV Board of Directors approved a proposed
name change and case definition involving porcine circovirus type 2 (PCV2).
The Porcine Circovirus Ad Hoc Committee, formed by the AASV board at
its 2006 annual meeting in Kansas City, proposed that the association
adopt the name “porcine circovirus associated disease (PCVAD)” for
the variety of clinical presentations currently described coincident
with PCV2 infections. This was an attempt by the committee to recognize
the variability in clinical signs currently associated with exposure
to this virus in pigs. The board approved the motion.
In addition, the committee also proposed a formalized case definition
to describe the minimum findings necessary to associate a given clinical
presentation with exposure to PCV2. To derive this case definition, the
committee elected to follow the methodology utilized by the Centers for
Disease Control and Prevention (CDC) when describing the emergence of
a previously unrecognized disease. The recommendation was also approved
by the board. |
|
Porcine circovirus associated disease (PCVAD) case definition
This case definition is considered to be a dynamic document which will
be altered as additional information becomes available. The CDC model
of describing the clinical expression of a new disease when a definitive
diagnosis is not known was used in developing the format for the following
case definition involving PCVAD.
PCVAD can be subclinical or include one or more of the following clinical
manifestations concurrently:
- Multisystemic disease with weight loss (formerly known as PMWS).
- High mortality: doubling of historical mortality rate without introduction
of a new known pathogen.
- Respiratory signs, including pneumonia.
- Porcine dermatitis and nephropathy syndrome (PDNS).
- Enteric signs, including diarrhea and weight loss.
- Reproductive disorders, including abortions, stillbirths, and fetal
mummification (diagnosis requires the presence of fetal myocarditis
associated with PCV2 antigen in lesions).
PCVAD is a broad categorization of multisystemic diseases that are confirmed
by documentation of the following histopathological findings in affected
pigs:
- Depletion of lymphoid cells in lymphoid tissues of the growing pigs.
- Disseminated granulomatous inflammation in one or more tissues (eg,
spleen, thymus, intestine, lymph node [sternal, bronchial, inguinal,
and mesenteric], lung, kidney, liver, tonsil).
- Detection of PCV2 within the lesions of growing pigs.
- Diagnosis of PCV2-associated reproductive disease requires the presence
of PCV2 antigen in fetal myocarditis lesions.
|
|
|
